Merck to Buy Terns Pharmaceuticals in $6.7 Billion Deal to Bolster its Cancer Portfolio Before Keytruda Patent Expires

news.law March 26, 2026

Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion as the pharmaceutical giant works on beefing up its cancer portfolio before a key patent on its cancer drug Keytruda expires in two years.

Merck received accelerated approval for Keytruda from the Food and Drug Administration in September 2014 to treat advanced or unresectable melanoma.

Supreme Court Rules that Cox Communications Bears No Liability for the Copyright Infringement Violations of its Customers

Wisconsin Man Found Guilty of Identity Theft and Fraud After Ordering Ballots Without Consent